- MarketWatch•5 days ago
Health-care shares tumbled Wednesday, making it the worst performing of the S&P 500 Index's ten sectors, as pricing issues in the industry flared up again, first inflamed by an astronomical price hike ...
- The Wall Street Journal•7 days ago
Pfizer’s $14 billion deal to buy Medivation and its prostate-cancer drug Xtandi is the latest in a long line of big pharmaceutical company acquisitions of smaller companies with prized assets. Here is ...
Merck & Co., Inc. (MRK.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
|Day's Range||90.60 - 90.60|
|52wk Range||71.00 - 90.60|
|1y Target Est||N/A|
|P/E Ratio (ttm)||49.70|
|Avg Vol (3m)||1,342|
|Dividend & Yield||N/A (N/A)|